You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

34 Results
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: 3-14
Version: 3
Jun 2025
Guidelines and Advice
Jun 2025
Drug
Other Name(s): Arimidex®
Jun 2025
Drug
Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™
Jun 2025
Drug
Jun 2025
Drug
Other Name(s): Adcetris®
Jun 2025
Drug
Other Name(s): Tafinlar®
Jun 2025
Drug
Other Name(s): Mekinist®
Jun 2025
Drug
Other Name(s): Rydapt®
Jun 2025
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue, 
Skin, 
Melanoma
Intent: Palliative
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma
Jun 2025

Pages